icon-pharma

• Market Access Consulting

Global Pharma Market Access: Pharmacoeconomics in Middle-income Countries

Introduction Many middle-income countries such as Egypt, South Africa, Malaysia, Thailand, and Brazil have pharmacoeconomic guidelines. These follow the recommendations by the International Society for Pharmacoeconomics and Outcomes Research but include country-specific differences. The variations respond to changes in how governments apply pharmacoeconomics and determine market access to pharmaceuticals and medical devices. This is also […]

Patient-Centered Research: Challenges in Gathering and Analyzing Patient Experience Data in a Real-World Setting

Introduction The FDA and EMA are committed to gathering more patient experience data for drug approvals and capturing real-world evidence for effectiveness evaluation. This post reviews ISPOR’s second plenary panel discussion in Vienna 2022 on patient-centered research and its challenges in gathering and analyzing patient experience data in a real-world setting, particularly within the EU. […]

Future European Collaboration among Health Technology Assessment and Regulatory Agencies

To review highlights of Plenary Session 1 on November 7, 2022: “The Convergence of Health Technology Assessment and Regulation: A New HTA Reality and Collaboration with Regulatory Agencies”.